Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060949 | 0.89 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL1610469 | 0.88 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL23174666 | 0.86 | KDM4E (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL27654860 | 0.86 | KDM4E (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL28188133 | 0.86 | KDM4E (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL1610343 | 0.86 | KDM4E (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL28188783 | 0.86 | KDM4E (0.44) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL537178 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL1611322 | 0.84 | PPARG (0.35) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL1379349 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177509-A1 | PRODUCTION OF BRIDGED ARTIFICIAL NUCLEOSIDES | NIPPON SHOKUBAI CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| EP-3950696-A1 | MANUFACTURING OF BRIDGED ARTIFICIAL NUCLEOSIDE | Nippon Shokubai Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| CN-113710680-A | Preparation of cross-linked artificial nucleosides | 株式会社日本触媒 | 2021-11-26 | — | — | CN | disclosed |
| EP-3239111-B1 | CURABLE COMPOSITION, TRANSFER FILM, FRONT PLATE OF IMAGE DISPLAY DEVICE, FRONT PLATE-INTEGRATED SENSOR, IMAGE DISPLAY DEVICE, AND MANUFACTURING METHOD FOR FRONT PLATE OF IMAGE DISPLAY DEVICE | FUJIFILM CORP (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020204022-A1 | MANUFACTURING OF BRIDGED ARTIFICIAL NUCLEOSIDE | 株式会社日本触媒 | 2020-10-08 | — | — | WO | disclosed |
| CN-110437046-A | Polymer containing fluorine atom and its utilize technical field | NISSAN CHEMICAL IND LTD | 2019-11-12 | — | — | CN | disclosed |
| US-10253360-B2 | BNA clamp method | BNA INC. (JP) | 2019-04-09 | — | — | US | disclosed |
| CN-105764885-B | The production method of acid and free-radical generating agent and acid and free radical | 富士胶片和光纯药株式会社 | 2018-11-09 | — | — | CN | disclosed |
| EP-2902499-B1 | BNA CLAMP METHOD | BNA INC (JP) | 2018-09-12 | — | — | EP | disclosed |
| US-10035927-B2 | Coloring composition for decoration, decorative material, base material having decorative material, transfer material, touch panel, and information display device | FUJIFILM CORPORATION (JP) | 2018-07-31 | — | — | US | disclosed |
| EP-0501656-B1 | New benzene derivatives having (NGF) production-promoting activity | SANKYO CO (JP) | 1997-01-22 | — | — | EP | disclosed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253360-B2 | BNA clamp method | SLC28A1, SLC28A2, NAAA | ALDH1A1 3467/4885CYP1A2 4749/4885CYP2C9 4301/4885 |
| US-20220177509-A1 | PRODUCTION OF BRIDGED ARTIFICIAL NUCLEOSIDES | TYMP, PNP, TYMS | ALDH1A1 1539/4885CYP1A2 1206/4885CYP2C9 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.